Abstract
The phosphoinositide 3-kinase (PI3K)/AKT pathway plays an important role in cancer development and progression. Mammalian target of rapamycin (mTOR) is a downstream effector of this pathway and is responsible for various cellular functions including mRNA translation, cell cycle progression and cellular proliferation. Activation of the PI3K/AKT pathway plays an important role in normal and neoplastic T and B cell proliferation. Abnormal activation of this pathway is seen in various hematologic malignancies. This knowledge has lead to an interest in evaluating the use of mTOR inhibitors in hematologic malignancies. The prototype mTOR inhibitor is rapamycin. Three other drugs are being evaluated in clinical trials. This review focuses on the biologic function of the PI3K/AKT/mTOR pathway and the mTOR inhibitors that are in clinical development for treatment of hematological malignancies.
Keywords: Hematological Malignancies, mammalian target of rapamycin (mTOR), cell cycle progression, Human Cancer, cellular proliferation, rapamycin
Current Cancer Therapy Reviews
Title: Role of mTOR in Hematological Malignancies
Volume: 4 Issue: 3
Author(s): Uzma Athar and Ajeet Gajra
Affiliation:
Keywords: Hematological Malignancies, mammalian target of rapamycin (mTOR), cell cycle progression, Human Cancer, cellular proliferation, rapamycin
Abstract: The phosphoinositide 3-kinase (PI3K)/AKT pathway plays an important role in cancer development and progression. Mammalian target of rapamycin (mTOR) is a downstream effector of this pathway and is responsible for various cellular functions including mRNA translation, cell cycle progression and cellular proliferation. Activation of the PI3K/AKT pathway plays an important role in normal and neoplastic T and B cell proliferation. Abnormal activation of this pathway is seen in various hematologic malignancies. This knowledge has lead to an interest in evaluating the use of mTOR inhibitors in hematologic malignancies. The prototype mTOR inhibitor is rapamycin. Three other drugs are being evaluated in clinical trials. This review focuses on the biologic function of the PI3K/AKT/mTOR pathway and the mTOR inhibitors that are in clinical development for treatment of hematological malignancies.
Export Options
About this article
Cite this article as:
Athar Uzma and Gajra Ajeet, Role of mTOR in Hematological Malignancies, Current Cancer Therapy Reviews 2008; 4 (3) . https://dx.doi.org/10.2174/157339408785294294
DOI https://dx.doi.org/10.2174/157339408785294294 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drug Resistance in Childhood Acute Myeloid Leukemia
Current Pharmaceutical Biotechnology Clinical Applications and Biosafety of Human Adult Mesenchymal Stem Cells
Current Pharmaceutical Design Gastroduodenal Disorders in Patients with CVID Undergoing Immunoglobulin Therapy
Current Pharmaceutical Biotechnology Immunomodulatory Activity of Mesenchymal Stem Cells
Current Stem Cell Research & Therapy Peptides Targeting Angiogenesis Related Growth Factor Receptors
Current Pharmaceutical Design From Systems Biology to Systems Pathology: A New Subspecialty in Diagnostic and Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Clinical Studies with Targeted Toxins in Malignant Glioma
Reviews on Recent Clinical Trials TNF Superfamily Protein-Protein Interactions: Feasibility of Small- Molecule Modulation
Current Drug Targets A Structural Insight into Hydroxamic Acid Based Histone Deacetylase Inhibitors for the Presence of Anticancer Activity
Current Medicinal Chemistry An Overview of Nanoformulated Nutraceuticals and their Therapeutic Approaches
Current Nutrition & Food Science Diaryl Urea: A Privileged Structure in Anticancer Agents
Current Medicinal Chemistry Emerging Treatments in Acute Lymphoblastic Leukemia
Current Cancer Drug Targets Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Cellular Senescence and Anti-Cancer Therapy
Current Drug Targets Cancer Stem Cells in Pediatric Brain Tumors
Current Stem Cell Research & Therapy The Interaction of Histone Deacetylase Inhibitors and DNA Methyltransferase Inhibitors in the Treatment of Human Cancer Cells
Current Medicinal Chemistry - Anti-Cancer Agents Cell Cycle Dependent Regulation of Intracellular Calcium Concentration in Vascular Smooth Muscle Cells: A Potential Target for Drug Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Management of Early Stage Cervical Cancer
Reviews on Recent Clinical Trials Aromatase Inhibitors: A New Paradigm in Breast Cancer Treatment
Current Medicinal Chemistry - Anti-Cancer Agents Nano-Delivery in Pediatric Tumors: Looking Back, Moving Forward
Anti-Cancer Agents in Medicinal Chemistry